Acetazolamide: Treatment of Psychogenic Polydipsia

Area of Science:

• Psychiatry
• Nephrology
• Endocrinology

Background:

• Psychogenic polydipsia is a condition characterized by excessive water intake, often associated with psychiatric disorders.
• Recurrent hyponatremia can be a dangerous complication of psychogenic polydipsia, leading to significant morbidity.
• Schizoaffective disorder bipolar type 1 is a chronic mental health condition requiring long-term management.

Observation:

• A patient with a five-year history of psychogenic polydipsia and recurrent hyponatremia, diagnosed with schizoaffective disorder bipolar type 1, was treated with acetazolamide.
• The patient's water balance was monitored using diurnal weight measurements (DWG), and sodium (Na⁺) levels were tracked via weekly comprehensive metabolic panels (CMP).
• Acetazolamide treatment led to a decreased compulsion to drink fluids and improved hyponatremia over a six-month observation period.

Findings:

• Acetazolamide demonstrated significant efficacy in managing psychogenic polydipsia, reducing excessive fluid intake.
• The treatment successfully corrected the patient's recurrent hyponatremia.
• The intervention was well-tolerated, with no reported adverse effects, and led to an improved quality of life for the patient.

Implications:

• Acetazolamide may represent a novel therapeutic option for psychogenic polydipsia and associated hyponatremia, particularly in patients with comorbid psychiatric conditions.
• This case highlights the importance of multidisciplinary management for complex cases involving psychiatric and electrolyte disturbances.
• Further research is warranted to explore the mechanism of action and broader applicability of acetazolamide in treating psychogenic polydipsia.